A pharmaceutical formulation of the cannabis extract, cannabidiol is being developed for those patients who do not respond to previous treatments for seizures associated with Lennox-Gastaut syndrome. This is taken as an oral solution.
Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)